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a  b  s  t  r  a  c  t
Cytokines, chemokines and growth factors (CCGFs) in human plasma are analyzed for iden-
tiﬁcation of biomarkers. However concentrations of CCGFs are very low; it is difﬁcult to
identify and quantify low abundance proteins in the presence of the high abundance pro-
teins (HAPs) unless HAPs are removed prior to analysis. However, there is a concern that
the  low abundance proteins such as CCGFs may also be removed during the HAP depletion
process. In this study, we have examined whether or not depletion of the HAPs enhances
detection of the CCGFs by immuno-assays. Top 14 HAPs were depleted from 10 healthy vol-
unteers’ plasma using MARS-14 immuno-depletion column and a total of 27 CCGFs were
analyzed by bead-based multiplexed immuno-assay. All 27 CCGFs were detected in neat
plasma (NP), 25 were detected in ﬂow through fraction (FT) and 21 were detected in bound
protein (BP) fraction. Concentrations of 22 CCGFs were signiﬁcantly higher in NP compared
to  FT and BP. Only one CCGF had higher concentration in FT compared to NP. The remaining
2  CCGFs were not different between NP and FT. It was counter-productive for the detectionPlasma of  24 CCGFs after HAP removal, primarily due to post-depletion protein precipitation and/or
re-suspension of pellets.
© 2014 The Authors. Published by Elsevier B.V. on behalf of European Proteomics
Association (EuPA). Open access under CC BY-NC-ND license.Human plasma is a protein rich complex bioﬂuid that rep-
resents a comprehensive snapshot of the processes occurred
in the body [1]. Concentrations of cytokines, chemokines and
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growth factors (CCGFs) in plasma have often been corre-
lated with disease progression and continue to be a source
of candidate biomarkers for a range of conditions. A recent
 European Proteomics Association (EuPA). Open access under CC BY-NC-ND license.
e u  p a o p e n p r o t e o m i c s 3 ( 2 0 1 4 ) 78–84 79
Table 1 – A summary of the depletion techniques and outcomes of high abundance protein depletion on downstream
analysis.
Depletion method Analysis method No. of non-speciﬁc
proteins depleted
Outcome of HAP
depletion
Refs.
Aurum Serum Protein
Minikit, ProteoExtract,
Albumin/IgG, MARS,
POROS Albumin/IgG
Removal Kit
1-D  & 2-D gels, MALDI
MS/MS
Not analyzed Increased number of protein spots
appeared on 2-D gels, not all spots
identiﬁed by MALDI MS/MS
[6]
Albumin depletion kits
from Viva Science,
Millipore, ABI, and
MARS 6
1-D  gels and 2-D DIGE gels,
MALDI MS/MS
0  76% increase in spot detection in MARS
columns depleted plasma compared to
crude plasma
[7]
ProteoExtract
Albumin/IgG removal
Kit, MARS 6, Proteome
Lab IgY-12
2-D  gels, Antibody
micro-arrays
115 spots on bound fraction
of IgY-12
234 spots detected in IgY-12 depleted
plasma compared to 159 spots in crude
plasma in the pH range 4–7
[8]
MARS 6, Cibacron blue 2-D gels Not analyzed Modest increase in number of spots on
2-D gel in MARS 6 depleted plasma
[9]
Mimetic blue column 2-D gels, MALDI MS Several plasma proteins Visualization of new proteins due to
removal of albumin and IgG
[10]
ProteoPrep20,
combination of Proteo
Extract and
ProteoPrep20
depletion, low
abundance protein
enrichment
2-D  LC MS/MS Not analyzed 25% more proteins identiﬁed after
ProteoPrep20 depletion compared to low
abundance protein enrichment method
[11]
ProteoMiner (protein
equalizer)
2-D  gels N/A 800 spots in protein equalized plasma
compared to 115 spots in crude
[12]
MARS 7 and 14 Peptide IEF followed by LC
MS/MS
23  low abundance 25% increase fractionated plasma
compared to crude
[13]
Zoom IEF fractionation 2-D gels, LC MS/MS N/A Proteins were fractionated in solution in
various narrow pH ranges for further
analysis.
[14]
ProteoMiner (protein
equalizer)
LC  MS/MS N/A 55% more proteins were identiﬁed in CPLL
treated plasma compared to crude
[15]
MARS 14; ProteoMiner
(protein equalizer)
2-D LC MS/MS 167 in MARS column 568, 497, and 1037 proteins were
identiﬁed from neat serum, MARS-14 and
PM equalized, respectively
[16]
ProteoMiner (protein
equalizer); albumin
and IgG depletion
2-D gels; MALDI MS Not analyzed 157, 427, 557 spots detected on 2-D gels
from crude, albumin and IgG depletion
and ProteoMiner treatment, respectively
[17]
ProteoPrep and API
(Abundant Protein
Immunodepletion)
Peptide IPG-IEF, LC MS/MS Not identiﬁed 38 new proteins were identiﬁed after
ultra-depletion which were not identiﬁed
in crude plasma
[18]
anti-albumin antibody
afﬁnity
chromatography and
SEC
RP-HPLC, 1-D SDS PAGE,
MALDI and LC MS/MS
35 proteins Not analyzed [19]
IgY 12 micro beads 1-Dand 2-D gels, LC MS/MS Not detected Many protein spots previously masked by
abundant proteins were revealed in the
depleted plasma and improved resolution
[20]
Molecular mass
fractionation
SELDI-TOF Low molecular mass
proteins bound to carriers
Total serum/plasma biomarker
concentration is largely determined by
the carrier protein clearance rate, not the
unbound biomarker clearance rate.
[21]
MARS 6 and 14,
Proteoprep 20
LC-MS/MS 45, 53 and 61 proteins in
MARS 6, 14 & ProteoPrep20,
respectively
Non-speciﬁc removal of low abundance
proteins; un-bound proteins were not
analyzed.
[22]
Montage Albumin
Deplete Kit
Microarray immunoassay Cytokines were depleted
with albumin
Concentrations of spiked cytokines were
reduced in albumin depleted plasma
compared to un-depleted plasma.
[23]
Proteoprep 20 Antibody microarray Not analyzed 86 proteins were detected with higher
intensities and 110 with lower intensities
after depletion
[24]
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study has summarized a list of reports on CCGFs that showed
various CCGFs were associated with various diseases, and
observed in various human body ﬂuids including plasma [2].
Although plasma is an ideal matrix for biomarker discovery,
it is extremely challenging to detect, analyze and characterize
the low abundance proteins such as CCGFs in the presence
of the high abundance proteins (HAPs) using gels or mass
spectrometry. Dynamic range of plasma proteins is over 10
orders of magnitude [3], for example, the top 9 HAPs cor-
respond to 90% and the top 21 proteins correspond to 99%
of total plasma proteins [4]. The HAPs (e.g., albumin, IgG,
etc.) interfere with identiﬁcation of the low abundance pro-
teins and therefore, HAPS are removed prior to downstream
analysis [5]. A large number of studies have shown that sig-
niﬁcant increase in total number of protein identiﬁcation
upon depletion of the HAP’s using various proteomic tech-
nologies (Table 1), [6–17]. Recently, an innovative IgY based
depletion technique has identiﬁed 38 new proteins that were
not previously identiﬁed in either neat plasma or depleted
by any other techniques [18]. Despite this, there is a con-
cern that the low abundance proteins including CCGFs may
also be inadvertently removed during the HAP depletion pro-
cess. Several studies have demonstrated that large numbers
of low abundance proteins were removed when albumin only
was depleted from plasma (Table 1), [19–21]. Moreover, when
multiple HAPs were depleted from plasma using an immuno-
depletion system, a total of 101 non-targeted proteins were
also removed [22]. In another study it was observed that after
albumin depletion from human plasma, recovery of spiked
cytokines ranged from 2% to 100% depending on cytokine [23],
analyzed by microarray immuno-assay. However, it is con-
troversial whether or not one should remove HAPs prior to
biomarker discovery from human plasma.
A recent report from our lab has demonstrated that a
large number of CCGFs (48 CCGFs analyzed) can be efﬁciently
detected and quantiﬁed from healthy human plasma, saliva
and urine using a bead-based multiplexed immuno-assay sys-
tem [2]. However, there is no report available to-date whether
depletion of the HAPs would even enhance detection of the
CCGFs further using the same multiplexed immuno-assay sys-
tem. In this present study, we have determined the presence
(at a detectable level, based on the lowest level of known con-
centration of the standard curve) or absence of 27 CCGFs from
non-depleted plasma (i.e., neat plasma, NP), depleted plasma
(i.e., ﬂow-through, FT) and also fraction that contains removed
HAPs (i.e., bound proteins, BP) and measured their concentra-
tions.
Ten healthy volunteers (5 male and 5 female) were
recruited for this study. Blood collected and samples were pre-
pared as previously described [2]. The study was approved by
the Macquarie University Human Ethics committee (reference:
5201100498). Prior to CCGF analyses, the top 14 HAPs (albumin,
IgG, transferrin, haptoglobin, alpha 1-anti trypsin, IgA, ﬁbrin-
ogen, alpha2 macroglobulin, alpha1 acid-glycoprotein, IgM,
apolipoprotein AI, apolipoprotein AII, complement C3, and
transthyretin) were depleted from NP samples using a multiple
afﬁnity removal system (MARS-14) immuno-depletion column
(Agilent, CA, USA) according to manufacturer’s instructions.
During the HAP depletion process, FT and BP fractions
were collected and concentrated by acetone precipitation. s 3 ( 2 0 1 4 ) 78–84
Fractionated proteins (FT and BP), neat plasma and one of
the two sets of serially diluted standards were also precipi-
tated by cold acetone (1 in 9 parts) overnight at −20 ◦C and
pelleted by centrifugation at 4000 × g for 60 min  at 4 ◦C. Neat
plasma and serially diluted standards were precipitated to
observe the effect of protein precipitation and followed by
re-solubilisation effect. The pelleted proteins form all the
samples and standards were re-suspended in PBS (same
volume as for the starting plasma volume prior to HAPs
depletion).
A 27-plex bead-based kit (Bio-Rad, CA, USA) was used to
measure concentrations of 27 CCGFs (listed in Table 2 and
the full names are described in Supplementary Table 1) from
precipitated (processed) and non-precipitated (un-processed)
NP, precipitated FT and precipitated BP (50 l in each well)
according to manufacturer’s instructions and also following
previous report [2]. Data were acquired, analyzed and standard
curves (Log(x)–Linear(y)) generated using the Bio-Plex Manager
v6.0 software (Bio-Rad, CA, USA). For calculation of concentra-
tions in non-precipitated NP non-precipitated standards, and
for precipitated NP, FT and BP samples precipitated standards
were used. Standard error, ANOVA and t-tests were calculated
using Microsoft Excel 2010 for comparison between sample
types (processed and un-processed NP, FT and BP). Any CCGFs
that were detected in less than 3 subjects were excluded from
statistical analysis.
Out of 27 CCGFs analyzed, all 27 CCGFs were detected in
both precipitated and non-precipitated NP. Of these, almost
all CCGFs were detected in all 10 subjects in NP (Table 2 and
Supplementary Table 2). In FT, 25 CCGFs were detected and
two CCGFs (IL-1ra and IL-12) were not detected at all. Most of
the detected CCGFs in FT were present in at least 9 subjects
(Supplementary Table 2). In BP, 21 CCGFs were detected and
6 CCGFs were not detected at all in any subject. In BP, CCGFs
were not detected in all the subjects but varied from 1 to 10
subjects for each CCGF (Table 2 and Supplementary Table 2).
There was no CCGF that was detected in BP but not detected in
FT. Detection of the lowest number of CCGFs in BP compared to
NP and FT was expected. In theory, BP should contain depleted
HAPs only. However, in our study, a signiﬁcant number of non-
targeted CCGFs were detected in BP suggesting many  CCGFs
were depleted along with HAPs, a ﬁnding supported by other
reports [19,22,23]. These non-speciﬁcally removed CCGFs are
most likely due to direct interaction between the CCGFs and
the targeted HAPs. For example, PDGF-bb (one of the CCGFs
that was detected in the BP fraction) is a known interac-
ting partner of -2 macroglobulin [25], one of HAPs that was
depleted in this study. It is also possible that CCGFs might have
depleted as a complex. For example, VEGF, a growth factor, was
detected in BP fraction is known to interact with vitronectin
[26] and vitronectin was non-speciﬁcally removed during albu-
min  depletion by an immuno-depletion column [19].
There were two CCGFs (IL-1ra and IL-12) detected in both
precipitated and non-precipitated NP but not detected in
either the FT or BP fractions. Even though concentrations of
these two CCGFs were in the medium range, they should still
have been detected in one of the fractions. However, it may
be possible that during HAP depletion process and/or pro-
tein precipitation step (FT and BP fractions), concentrations of
these two CCGFs were further diluted out. It has been reported
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Table 2 – Average concentrations of CCGFs in neat plasma, neat plasma after acetone precipitation, ﬂow through and bound protein fractions.
Neat plasma without processing Neat plasma after precipitation Flow through Bound protein
CCGFs Average (pg/ml) SE n Average (pg/ml) SE n Average (pg/ml) SE n Average (pg/ml) SE n
IL-1b 2.07 0.31 10  0.61 0.07 10 0.54 0.04 10 0.25 0.05 10
IL-1ra 94.21 16.17 10 17.59 1.96 10 0 0 0 0 0 0
IL-2 11.22 2.92 10  2.82 0.87 8 4.31 0.38 9 4.21 0.27 7
IL-4 2.97 0.42 10  0.45 0.06 10 0.23 0.04 9 0 0 0
IL-5 5.95 0.98 10  0.40 0.12 4 0.19 0.04 8 0 0 0
IL-6 8.11 1.56 10  2.22 0.54 10 0.31 0.13 4 6.32 0 1
IL-7 6.29 0.97 10  25.73 2.96 10 0.70 0.13 10 0.2 0.02 10
IL-8 31.09 5.00 10 6.05 0.79 10 1.41 0.14 9 0.41 0.16 4
IL-9 6.13 1.29 9 0.45 0.14 9 0.51 0.09 8 0.30 0.14 5
IL-10 23.65 8.85 10 2.20 0.14 10 2.63 0.19 9 1.74 0.28 10
IL-12 (p70) 71.97 54.93 9 4.40 0.77 10 0 0 0 0 0 0
IL-13 13.65 4.14 10 8.84 1.64 10 0.33 0.03 10 0.18 0.02 10
IL-15 8.35 1.27 7 30.77 2.77 10 20.45 1.41 9 11.38 1.05 7
IL-17 42.91 6.91 10 4.63 0.84 10 8.81 2.21 9 0 0 0
Eotaxin 37.19 5.63 10 26.98 4.10 10 19.54 2.52 10 0 0 0
FGF b 27.9 3.48 9 15.21 2.00 10 13.36 0.69 9 11.44 1.59 7
G-CSF 73.17 12.51 10 8.12 2.00 9 4.47 0.47 9 1.16 0.29 5
GM-CSF 13.72 3.68 9 20.42 3.69 10 67.74 1.91 9 74 2.99 9
IFN-g 72.97 13.3 10 9.86 1.55 10 1.80 0.31 8 0.59 0 2
IP-10 252.74 55.06 10 81.40 19.06 10 85.71 21.88 9 3.54 0.76 7
MCP-1 (MCAF) 28.19 3.55 10 24.98 3.88 10 13.95 1.68 9 0.59 0.23 2
MIP-1a 2.49 0.34 10 1.10 0.14 10 0.61 0.03 10 0.44 0.05 10
PDGF-bb 169.48 58.75 10 120.36 50.57 10 290.02 148.52 9 16.37 9.49 7
MIP-1b 21.97 3.24 10 22.29 3.77 10 10.82 1.88 10 0.68 0.17 6
RANTES 1732.82 235.88 10 1739.24 207.80 10 997.10 155.22 10 14.96 6.68 7
TNF-a 43.92 7.72 10 3.77 0.53 10 3.58 0.43 9 1.22 0.37 6
VEGF 16.79 2.54 10 21.51 4.37 10 23.32 4.96 9 4.31 0.69 6
Concentrations of all the CCGFs for individual volunteer are shown in Supplementary Table 2. CCGFs = cytokines, chemokines and growth factors, SE = standard error, n = number of subjects.
o m i c82  e u  p a o p e n p r o t e 
that protein recovery was reduced due to protein precipitation
[27,28].
Average concentrations of most of the CCGFs were signif-
icantly higher in un-processed NP compared to processed NP
(after precipitation, centrifugation and re-suspension of pel-
let), FT and BP except for IL-7, IL-15, and GM-CSF (Table 3).
This loss of recovery in processed NP indicates overall loss
of recovery in FT is primarily due to precipitation of pro-
teins and/or re-suspension of pellets. However, IL-7 was
signiﬁcantly higher (P ≤ 0.05) in processed NP followed by un-
processed NP, FT and BP, respectively. IL-15 was signiﬁcantly
higher (P ≤ 0.05) in processed NP followed by FT, BP and un-
processed NP. However, there was no signiﬁcant difference
between un-processed NP and BP for IL-15. GM-CSF was signif-
icantly higher (P ≤ 0.05) in BP and FT followed by un-processed
NP and processed NP. There was no signiﬁcant difference
between BP and FT, and processed or un-processed NP for GM-
CSF. There was no signiﬁcant difference between sample types
for PDGF-bb (Table 3).
Our main purpose of this work was to observe whether
depletion of HAPs from human plasma using an immuno-
depletion column increases or decreases the detection of
CCGFs using a bead based multi-plex immuno-assay sys-
tem. High-performance liquid chromatography (HPLC)-based
immuno-depleted samples cannot be analyzed without
Table 3 – Concentration difference between neat plasma (NP), n
through (FT) and bound protein (BP) fractions of detected CCGFs
CCGFs NP (pg/ml) NP-ppt (pg/ml) FT (pg/ml) BP (pg
IL-1b 2.07 a 0.61 b 0.54 b 0.25 c 
IL-1ra 94.21 17.59 0 0 
IL-2 11.22 a 2.82 b 4.31 b 4.21 b
IL-4 2.97 a 0.45 b 0.23 c 0 
IL-5 5.95 a 0.4 b 0.19 b 0 
IL-6 8.11 a 2.22 b 0.31 c 0 
IL-7 6.29 b 25.73 a 0.7 c 0.2 d 
IL-8 31.09 a 6.05 b 1.41 c 0.41 d
IL-9 6.13 a 0.45 b 0.51 b 0.3 b 
IL-10 23.65 a 2.2 b 2.63 b 1.74 b
IL-12 (p70) 71.97 4.40 0 0 
IL-13 13.65 a 8.84 a 0.33 b 0.18 c 
IL-15 8.35 c 30.77 a 20.45 b 11.38 c 
IL-17 42.91 a 4.63 b 8.81 b 0 
Eotaxin 37.19 a 26.98 a 19.54 b 0 
FGF basic 27.90 a 15.21 b 13.36 b 11.44 b
G-CSF 73.17 a 8.12 b 4.47 b 1.16 c 
GM-CSF 13.72 b 20.42 b 67.74 a 74 a 
IFN-g 72.97 a 9.86 b 1.8 c 0 
IP-10 252.74 a 81.4 b 85.71 b 3.54 c 
MCP-1 (MCAF) 28.19 a 24.98 a 13.95 b 0 
MIP-1a 2.49 a 1.1 b 0.61 c 0.44 d
PDGF-bb 169.48 120.36 290.02 16.37 
MIP-1b 21.97 a 22.29 a 10.82 b 0.68 c 
RANTES 1732.82 a 1739.24 a 997.1 b 14.96 c 
TNF-a 43.92 a 3.77 b 3.58 b 1.22 c 
VEGF 16.79 a 21.51 a 23.32 a 4.31 b
Any CCGF detected in less than three subjects for each sample type (NP, N
was performed when CCGFs were detected in all four or three sample type
overall F test was signiﬁcant (P ≤ 0.05), the mean values were compared w
represent the signiﬁcant difference between the sample types. i.e., a: high
The same letters indicate the difference between the samples is not signiﬁ s 3 ( 2 0 1 4 ) 78–84
processing due to sample dilution and buffer system used for
depletion. Sample processing includes concentration of sam-
ples either by precipitation or ultra-ﬁltration, re-suspension
of pellets and in some cases needs to perform an additional
step, buffer exchange, for assay compatibility. This means
post-depletion sample processing is associated with deple-
tion process but not with neat samples. Our main comparison
is to observe the difference between neat plasma (no sam-
ple processing is required for analysis) vs depleted plasma
(depleted samples must go through sample processing prior
to analysis) and the data are presented in this manuscript
accordingly. It was observed that overall loss of recovery is
associated with depletion process. However, to ﬁgure out the
source of loss of recovery, we  have processed in parallel neat
plasma and also serially diluted standard, the same standard
set that was used for calculation of concentrations of CCGFs
for non-precipitated neat plasma. It was observed that there
were some losses of recovery in precipitated neat plasma com-
pared to non-precipitated plasma due to sample processing
alone (acetone precipitation only, no HAP removal involved)
and the losses were enhanced due to removal of HAPs. Data
presented in the manuscript suggests that loss of recovery in
FT is mainly due to combination of post-depletion precipi-
tation of proteins and/or re-suspension of pellets, and non-
speciﬁc removals of CCGFs (Table 3, Supplementary Table 3).
eat plasma after acetone precipitation (NP-ppt), ﬂow
.
/ml) P-value (ANOVA) F-value (ANOVA) P-value (t-test)
5E−9 25.51 –
– – 1.12E−3
 7.15E−3  4.86 –
3.38E−8  35.83 –
2.49E−5  19.5 –
6.14E−4  10.34 –
5.31E−14 59.26 –
 7.33E−8  23.22 –
5.31E−6  15.25 –
 2.85E−3  5.66 –
– – 0.25
1.51E−4  8.91 –
1.83E−8  26.56 –
1.21E−6  24.08 –
0.02 4.29 –
 5.21E−5  10.77 –
1.39E−7  21.77 –
2.46E−16 95.34 –
2.69E−6  22.38 –
1.46E−4  9.28 –
0.01 5.03 –
 7.07E−9  24.79 –
0.22 1.56 –
7.57E−5  10.14 –
1.44E−6  15.89 –
5.39E−8  22.84 –
 0.02 3.83 –
P-ppt, FT and BP) was excluded from statistical analysis. An ANOVA
s and t-test was used when detected in two sample types. When the
ith t-text. The letters at the end of the concentrations in each row
est concentration, b: second highest, c: third highest and d: lowest.
cant. CCGFs = cytokines, chemokines and growth factors.
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We  have observed an issue with the multiplex analysis
ystem which is concentrations of various CCGFs is very dif-
erent in plasma but they are analyzed simultaneously in a
ingle assay. This is less than ideal because concentrations of
ajority of the CCGFs are very low but concentrations of some
CGFs very high. Ideally, for detection of some higher concen-
rations CCGFs plasma samples should be diluted out prior to
nalysis and for detection of the other lower concentrations
CGFs, plasma should be analyzed neat if not concentrated
rior to analysis. But in real life, samples are analyzed either
iluted or un-diluted for the detection of multiple CCGFs in a
ingle assay due to high cost associated with optimization of
ssay conditions.
In conclusion, the highest numbers of CCGFs were detected
n both un-processed and processed NP followed by FT and
P. Out of 27 CCGFs analyzed, detection level of GM-CSF only
as improved by HAP depletion. Overall HAP depletion was
ounter-productive for the detection of 24 CCGFs primarily
ue to post-depletion precipitation of proteins and/or re-
uspension of pellets, and also for non-speciﬁc removals of
CGFs. Although other reports showed more  proteins were
dentiﬁed after HAP depletion using mass spectrometry or gel
ased proteomics, however, it appeared that antibody based
nalytical technique is capable of identifying similar or more
roteins in neat plasma compared to HAP depleted plasma.
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